Literature DB >> 8675284

Antibody-mediated shift in the profile of glycoprotein A phenotypes observed in a mouse model of Pneumocystis carinii pneumonia.

F Gigliotti1, B A Garvy, A G Harmsen.   

Abstract

It is well established that Pneumocystis carinii has the molecular capability for variation of a major surface antigen, glycoprotein A (gpA). However, the extent of expression of gpA variation among P. carinii organisms infecting a single host and whether this variation has any impact on host-parasite immunological interactions is unknown. Using a mouse model of P. carinii pneumonia, we were able to demonstrate the expression of more than one gpA phenotype in a closed population of infected mice. Administration of monoclonal antibody (MAb) 2B5, which is specific for one of the gpA phenotypes, resulted in a marked diminution in the frequency of this particular gpA phenotype in the population of organisms. This effect was due to a loss of trophozoites bearing the specific epitope recognized by MAb 2B5; cysts bearing the same epitope appeared unaffected. Interestingly, P. carinii was unable to introduce a new phenotype into the population to compensate for the loss of trophozoites bearing the epitope recognized by MAb 2B5. Discontinuing administration of MAb 2B5 allowed the MAb 2B5-binding phenotype to reemerge. This finding suggests that the phenotype recognized by MAb 2B5 was continually produced even when MAb 2B5 was present. Thus, although P. carinii exhibited a form of antigenic variation, it did not appear able to rapidly introduce new phenotypes into the population in response to destruction by antibodies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675284      PMCID: PMC174013          DOI: 10.1128/iai.64.6.1892-1899.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

Review 1.  Molecular genetics of antigenic variation.

Authors:  P Borst
Journal:  Immunol Today       Date:  1991-03

2.  Antigenic variation in Giardia lamblia: cellular and humoral immune response in a mouse model.

Authors:  B Gottstein; G R Harriman; J T Conrad; T E Nash
Journal:  Parasite Immunol       Date:  1990-11       Impact factor: 2.280

3.  Purification and initial characterization of a ferret Pneumocystis carinii surface antigen.

Authors:  F Gigliotti; L R Ballou; W T Hughes; B D Mosley
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

4.  Glycoprotein A is the immunodominant antigen of Pneumocystis carinii in mice following immunization.

Authors:  F Gigliotti; T McCool
Journal:  Parasitol Res       Date:  1996       Impact factor: 2.289

5.  Antigenic variation in trypanosomes.

Authors:  K Vickerman
Journal:  Nature       Date:  1978-06-22       Impact factor: 49.962

6.  Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models.

Authors:  F Gigliotti; W T Hughes
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

7.  Analysis of the developmental stages of Pneumocystis carinii, in vitro.

Authors:  M T Cushion; J J Ruffolo; P D Walzer
Journal:  Lab Invest       Date:  1988-03       Impact factor: 5.662

8.  Monoclonal antibodies to Pneumocystis carinii: identification of specific antigens and characterization of antigenic differences between rat and human isolates.

Authors:  J A Kovacs; J L Halpern; B Lundgren; J C Swan; J E Parrillo; H Masur
Journal:  J Infect Dis       Date:  1989-01       Impact factor: 5.226

9.  Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice.

Authors:  A G Harmsen; M Stankiewicz
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

10.  Clearance of Giardia muris infection requires helper/inducer T lymphocytes.

Authors:  M F Heyworth; J R Carlson; T H Ermak
Journal:  J Exp Med       Date:  1987-06-01       Impact factor: 14.307

View more
  17 in total

Review 1.  Immunological features of Pneumocystis carinii infection in humans.

Authors:  P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  Expression, structure, and location of epitopes of the major surface glycoprotein of Pneumocystis carinii f. sp. carinii.

Authors:  M J Linke; S M Sunkin; R P Andrews; J R Stringer; P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

3.  Human immunodeficiency virus-infected patients with prior Pneumocystis pneumonia exhibit increased serologic reactivity to several major surface glycoprotein clones.

Authors:  K R Daly; J V Koch; N J Shire; L Levin; P D Walzer
Journal:  Clin Vaccine Immunol       Date:  2006-10

Review 4.  Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases.

Authors:  Arturo Casadevall; Liise-Anne Pirofski
Journal:  Cell Host Microbe       Date:  2012-05-17       Impact factor: 21.023

5.  Passive immunization of neonatal mice against Pneumocystis carinii f. sp. muris enhances control of infection without stimulating inflammation.

Authors:  Kerry M Empey; Melissa Hollifield; Kevin Schuer; Francis Gigliotti; Beth A Garvy
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

6.  Characterization of major surface glycoprotein genes of human Pneumocystis carinii and high-level expression of a conserved region.

Authors:  Q Mei; R E Turner; V Sorial; D Klivington; C W Angus; J A Kovacs
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

7.  Epitope mapping of a protective monoclonal antibody against Pneumocystis carinii with shared reactivity to Streptococcus pneumoniae surface antigen PspA.

Authors:  Jesse Wells; Francis Gigliotti; Patricia J Simpson-Haidaris; Constantine G Haidaris
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

8.  Antigenic properties of recombinant glycosylated and nonglycosylated Pneumocystis carinii glycoprotein A polypeptides expressed in baculovirus-infected insect cells.

Authors:  C G Haidaris; D J Fisher; F Gigliotti; P J Simpson-Haidaris
Journal:  Mol Biotechnol       Date:  1998-04       Impact factor: 2.695

9.  Combination exposure to zidovudine plus sulfamethoxazole-trimethoprim diminishes B-lymphocyte immune responses to Pneumocystis murina infection in healthy mice.

Authors:  David J Feola; Beth A Garvy
Journal:  Clin Vaccine Immunol       Date:  2006-02

10.  Immunization with Pneumocystis carinii gpA is immunogenic but not protective in a mouse model of P. carinii pneumonia.

Authors:  F Gigliotti; J A Wiley; A G Harmsen
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.